MDCO-216: Phase I/II ongoing

An IDMC recommended continuation of the double-blind, placebo-controlled, international Phase I/II MILANO-PILOT trial evaluating 20 mg/kg IV MDCO-216 weekly for 5 weeks based on a planned interim anal...